

Organoids As a form of Modern Day Silver Lining In Blood Cancer

Abstract— Blood Cancer-in the shape of carcinogenesis, is worldwide recognized, as a recent time catastrophe. Its unique capability of sustaining its dormancy, vulnerabilities, of drug screening methodologies, and most importantly therapeutic resistance of tumor affected stem cells has transformed blood cancer, as hardly curable. To face this challenge; Organoids are figured out to be a possible solution. From a researcher's point of view organoids are generally 3D structured in (vivo) clusters of stem cell molecules, showcasing bio-active capabilities. However, the lower success rate of organoids, bespeaking its initial stages of preclinical level of studies. In addition, most of these models & their implications just only been limited to in (vivo) principles and various forms of cancer exemplifying; Blood lymphoma. Interestingly, some recent milestones of organoids in different research models on metastasis reflects the glimpses of hopes. At this present study, we have worked on organoids and their possible involvement in blood cancer. We have emphasized on organoid modellings both in (vivo) and in (vitro) cell culture, which are some excellent sources for cell analysis. Presently, we have established a model where a Nano-sized in (vitro-vivo) cell clustering's of organoids with an MRI scanning technique been utilized to build a more precise and useful therapeutic tool. This innovative approach would help us to identify the tumors that won't respond to any conventional therapies. Also in our studies the organoids have shown; active cellular level of immunomodulation, leading to a proper signal transduction. As a consequences, this revolutionary model creates opportunities for a better outcome in terms of diagnostics and therapeutics.

Key word: *Blood cancer, in (vivo-vitro) models, Organoids, Revolutionary model.*

1. INTRODUCTION

From the preface of the eclipse of an unknown erstwhile to the dawns of the most advanced 21st century, Blood cancer has always been figured out to be an unbridled deterrent against the existence of human souls. Leukemia, Lymphoma, and Myeloma [26] are all of the three different existing forms of blood cancer, reflecting the various levels of its fatality and pathogenicity. Its higher percentage of its morbidity resembling the atrocious side of this havoc. According to some recent data interpretations, Blood cancer is being primarily termed as; responsible for the deaths of almost a single living person within a span of every 9 minutes in USA in 2017[23]. Previously utilized drug therapeutics and treatment modalities such as; Surgery, Chemotherapy, Radiotherapy and recently experimented immune therapeutics showing a class of higher success rate by dwindling the death percentage by almost 70 percentiles. However, they are still unable to eradicate this

27 apocalypse. The primary analytical reports symbolizing the main obstacles behind
28 the treatment policies of blood cancer are:

29

30 • The inability to target and the supreme capability of the resistance of human stem cells
31 against various types of cancerous medications.

32 •Lack of cancer epigenetics profiling and specificity suggesting the unfortunate aspects of
33 its inability to treat tumor, even within the same origin and similar characteristics.

34 •Metastasis of cancer tumor cells paving a way for some research output on something
35 effective and advanced, especially in blood cancer.

36 •The Non-specific nature of cancer symptoms and the problems associated with cancer
37 diagnosis making it harder to treat.

38

39 **Example:** The current imaging tool PET-CT technique is still unable to predict the responses
40 with reliable accuracy and not that much effective towards a more individualized treatment
41 policies, urging on the necessity of innovative therapeutic solutions like; Organoids. That's
42 why this proposed theory surrounding the active responses of organoids as an anti-
43 oncogenic agent, has a huge potential to fulfill. Nevertheless the lower success rate of
44 organoids could be used as an obstruction against this proposed one, but here the issued
45 researchology working on the whole aspect, is completely based on the liabilities of those
46 upwardly discussed processes and an advancement of organoid theorem. Furtherly, the
47 vulnerabilities of 2D cell cultures in terms of-

48

49 • The Inability to stimulate the micro-environment and organ specific functions and

50

51 • Lacking's of the proper genetic heterogeneity of original tumors. Indicating the soften
52 corner in this route of analysis.

53

54 Whereas, the activity of 3D in (vivo-vitro) model featuring the followings:

55

56 • The effectiveness in both in (vivo) and in (vitro) counterparts and

57

58 • The performance of the assay techniques associated with a purpose to differentiation,
59 diagnosis, and its usefulness in vivo self-proliferation and efficiency in the treatment of
60 individually affected cancer cells [2].

61

62 From an additional point of view, MRI scanning techniques could be utilized as a trump card
63 in a similar scenario. This Magnetic Resonance Imaging technique possessing, the ability to
64 add a new dimension to the ongoing procedure has the ability by making the diagnosis and
65 prognosis process a far more precise and effective in nature. Therefore, the organoids
66 could easily be available to resolve the missing puzzle.

67

68

69

70

CHALLENGES ASSOCIATED WITH BLOOD CANCER:

71

72

The obstacles following the treatment of various blood cancer are:

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118

- While targeting cancer stem cells
- Drug resistance properties of stem cells
- Lack of cancer epigenetic profiling & specificity of existing Epi-drugs.
- Association with cancer diagnosis makes it difficult to treat.
- Unavailability of effective biomarkers in blood cancer.
- Limitations of conventional chemotherapeutic agents.
- Metastasis possessing a huge obstacle to the treatment of cancer.

MECHANISM OF BLOOD CANCER:

The stem cells originating from the bone marrow leading to the development of Hematopoiesis. Usually, stem cell molecules are constantly divided to produce a new cell. Whereas, in blood cancer it may sometimes go through a passage of unnatural cell division, anemia or the signal transduction pathway gets severely hampered. AS a result, the differentiation, transduction, and repair mechanism gets completely damaged, as well as the cell proliferation process.

The greatest armory of these models is just not only to aid us to handle the metabolic changes [2], but also to help us to express the genes. As a consequences, **Normal progenitor cells leading to repair and regeneration after the possible occurrence of damages.**

RESEARCH PROCEDURE:

In recent times, the success of both in (vivo) & in vitro organoid cell culture & its wonderful supremacy, while showing mimicry, providing the characteristics of heterogeneity [2].

CULTURE SYSTEM OF BLOOD CANCER:

119
120
121
122

This proposed research model is composed of the following components:

Table 01:

Matrigel Matrix, ECM extract, Advanced DMEM/F12, Gluta Max, HEPES, Noggin, R-Spondin-1, Nicotinamide, A-83-01, Y27632, Gremlin 1, Darbepoetin-alpha, Peginesatide, Romiplostim, WNT pathway inhibitor, Hedgehog pathway inhibitor, Farnesyl transferase inhibitor, Aurora A kinase inhibitor, Histone deacetylase, HSP90, Proteasome inhibitors, Nicotinamide.

123
124
125
126
127
128
129

It is to be noted that here the existence of ECM substituents is the differentiating constituents between 2D & 3D organoid cell culture[2], where the advanced DMEM/F12 is being utilized as the ideal cell culture media.

Table 02 [13]:

NAME OF THE COMPONNETS OF ADVANCED DMEM/F12:
Glucose
Non-essential Amino Acids
Sodium Pyruvate
Phenol Red

130
131
132
133
134
135
136
137
138
139
140

WHY ADVANCED DMEM/F-12 IS UNIQUE:

The reasons to be bolded behind the usage of Advanced DMEM/F-12 are:

- Inexistence of L-glutamine
- There isn't any use of HEPES
- Reduced (FBS) supplementation compared to classics, where reduction occurred by almost (50-60) percentiles [13]

141
142
143
144
145
146
147

GENERAL OVERVIEW:

148
149
150
151
152
153
154
155

Self-developing capability among inherently affected stem cells is a renowned assumption among scientists and has initiated researchers to develop a 3D in (vivo-vitro) cell culture models from primary tissues of bone marrow [2]. Both in (vivo-vitro) models of organoids **representing a more reliable and idealistic response compared to usual cell lines, outlasting recapitulation and manipulation capacity [2].**

156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193

WHY NANO-MRI SCANNER:

MRI Scanner is an ideal media to diagnose. Magnetic Resonance Imaging technique uses strong magnetic field gradients and in here, The Nano-ranged wave technology to generate the in (vivo) images of the human body on different slices like; Sagittal, Axial, Limbic to get an ideal diagnosing outcome.

It's advantageous to use an MRI scanner, as it doesn't have any ionizing radiation technology leading to toxicity. Before going through the MRI scanning process, the subject is being injected by the dye. Aftermath, Nano ranged estimation aids us to observe and diagnose.

The greatest asset of this type of MRI scanners is the ability to get a gradual improvisation, as the more

Advanced generation reflects on the shorter passage of scanning period.


Though it usually takes around (30-60) minutes [14] to make a complete scan, here it has taken a figure somewhere close to (10-15) minutes.

[NOTE: The ideal 3D organoid cell culture having Lamnin riched Matrigel, Growth factors & small cell inhibitors][2]

In additional sense,

- It would aid the diagnosis quite accurately.
- Greater application of the media.
- It helps in the 3D culture of organoids

(IN VITRO MODEL)



194
195
196
197
198
199
200

MRI SCANNER [20] NANOTECHNOLOGY [24]

201
202
203
204
205
206




DIAGNOSIS [17]

207
208
209
210
211



BONE MARROW [25]

212
213



STEM CELL [30]

214
215
216
217

(MINCE)

218
219
220



221
222
223
224
225
226
227

SMALL FRAGMENTS

(COLLAGENASE TYPE 2 & DIGESTION)

228
229



TUMOR STEM CELLS [31]

230
231
232
233
234
235

(ADMEM/F12)

(ENDOSTEAL MATRIX)(FIBRINOCETIN/CI)

236
237



Matrigel +Organoid

238
239

Centrifugation

240
241
242
243
244
245
246
247



248
249
250
251
252
253
254

255
256
257
258
259
260
261
262

263
264
265
266
267
268


269
270
271
272
273
274
275

276
277
278
279
280
281
282
283
284
285
286
287
288
289
290



CENTRIFUGED SAMPLE [18]

(ISOLATED STEM CELL)




TUMOR STEM CELL [31]



INCUBATION[19]



BLOOD SAMPLE [19]



HUMAN BLOOD SAMPLE [32]




Matrigel +Organoid

291
292
293
294
295



INJECTION [21]



IN VIVO (RAT MODEL) [27]

296
297
298
299
300

Fig. 1: Flow chart for in (vivo-vitro) establishment of Blood Cancer.

301
302
303
304
305
306
307
308
309
310
311

IN (VIVO) SCENARIO:

Transgenic mice models is implemented to resume the experiment in (vivo) analytical condition. Here, the mutated genes of human blood cancer is induced to the growth of blood cancer affected cells. MRI analytical technique is being widely designed for the observational studies.

312
313
314
315
316
317

IN (VITRO) SCENARIO:

The economically balanced, genetically manipulated, and flexibly molded in (vitro) model shows a series of active phenotypic responses. Proving its worth as a recognized assay.

318
319
320
321
322
323
324
325
326

Enzymatic expression in blood cancer is a good option to target. That's why the inhibitors of those channels and their enzymatic activities of the protein level inhibitors been activated. Utilization of Nano wavelength for the purpose of analyzing the targets to establish a proper study model, possessing a superior accuracy and greater efficiency to detect deep lying tumors with relatively ease.

327
328
329

**TABLE 03:
GROWTH FACTORS & INHIBITORS APPLIED IN ORGANOID CELL CULTURE**

<u>NAME</u>	<u>FUNCTION</u>	<u>STRUCTURE/SOURCE/ COMPONENTS</u>
GREMLIN 1	Inhibition of predominant BMP2 & BMP4 in limb buds allows	<ul style="list-style-type: none"> •Embryonic fibroblast •Furin like domain •184 Amino acid glycoprotein

	the transcriptional upregulation of FGF'S & SHH ligands.	
R-SPONDIN-01	Facilitation of the growth of metastasis[2]	<ul style="list-style-type: none"> •Chromosome •2cysteine ring •1 thrombospondin type 1 domain
NOGGIN	Promotion of bone metastasis of some cancers & association with tumorigenesis of primary bone malignancies [2]	<ul style="list-style-type: none"> •HGNC:HGNC:7866
AURORA A KINASE INHIBITOR	<ul style="list-style-type: none"> •Regulation of serine/threonine kinases •Anti-cancer agents 	encoding aurora A,B, & C.
FARNESYL TRANSFERASE INHIBITOR	A preventive function	A 4 Amino acid sequence at the carboxyl terminus of a RaS. (48KDa & 46KDa)
HISTONE DEACETYLASE INHIBITOR	Inhibition of histone deacetylase	2classes; HDAC & HDI
PROTEASOME INHIBITOR	Blocks proteasomes	Proteolytic site on the Eukaryotic cells
Wnt PATHWAY INHIBITOR	Promotion of cancer & progression of it[42]	<ul style="list-style-type: none"> •WNT ligand or receptors •3signaling pathways: canonical, non-canonical planar cell polarity, non-canonical WNT/calcium
FLT3	<ul style="list-style-type: none"> •Formation of fms regulated tyrosine kinase 3 •Signal transduction [28] 	HGNC:HGNC:3765[28]
A-83-01	<ul style="list-style-type: none"> • A transforming growth factor beta inhibitor suppresses the proliferation of organoids [2] 	<ul style="list-style-type: none"> •C25H19N9S • <u>HHI</u>: Results of aberrant component of the Hedgehog signaling pathways. •3different classes; Shh, GLI, SMO [29]
DARBEPOETIN	Stimulates	C815H1317N233O241S5

ALPHA	<ul style="list-style-type: none"> •erythrope- Sis •Anemia 	
PEGINESATIDE	<p>Stimulates</p> <ul style="list-style-type: none"> •Anemia •It mimics the structure of Erythropoietin & promotes the RBC development 	C231H350N62O58S6[C2H4O] _n
ROMIPLOSTIM	A hormone that regulates platelet production	<ul style="list-style-type: none"> •C2634H4080N722O790S18[47] •Analogue of thrombopoietin
NICOTINAMIDE	A Vitamin PP Is a nutrient required for long term organoid culture	<ul style="list-style-type: none"> •C6H6N2O[48] •Nicotinic acid or 3cyanopyridine
Y27632	<ul style="list-style-type: none"> •Inhibition of Rho kinase[2] •Improves culture[2] 	C14H21N3O
HEDGEHOG PATHWAY INHIBITOR	<ul style="list-style-type: none"> •Inhibits the Growth of cell[•Activates tissue repairmen and cell proliferation 	<ul style="list-style-type: none"> •3FDA approved inhibitors: Vismodegib, Erismodegib, Smoothened •It's a kind of glycoproteins
MATRIGEL INHIBITOR	<ul style="list-style-type: none"> • Mimicry in vivo 2D & 3D environments •Improvement of the differentiation of both normal and transformed anchorage dependent epithelial cells 	Sarcoma cells
HSP 90 INHIBITOR	<ul style="list-style-type: none"> •Inhibits collagen I & ii • Inhibits Matrix metalloprot- Eanase-3 to Reduce cell Metastasis 	3 types of Natural product geldanamycin (C29H40N2O9), radicicol(C18H17ClO6), 17AAG(C31H43N3O8)

--	--	--

330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371

CLASSIFICATION OF BLOOD CANCER:

Blood cancer can easily be divided into the following way:





Figure 2: Classification of blood cancer


ACUTE LYMPHOBLASTIC LEUKEMIA:



372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402

Figure 02 : Acute Lymphoblastic Leukemia [6]

MECHANISM:




MECHANISM OF INHIBITORS:

- Inhibits tyrosine kinase inhibitors.

403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448

•Activates proteins by signal transduction cascades.



[NOTE: Tyrosine kinase inhibitors ability to deprive Tyrosine kinase to access HSP 90]

UNDER PEER REVIEW

ACUTE MYELOGENOUS LEUKEMIA:





Figure03: Acute Myelogenous Leukemia [7]




INHIBITORS:

- Histone deacetylase.
- Tyrosine kinase inhibitors.

473
474
475
476
477
478
479
480
481

CHRONIC LYMPHOCYTIC LEUKEMIA:



482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499

Figure04: Chronic Lymphocytic Leukemia [8]

Chronic Cancer results as the bone marrow produces a handful number of amount of lymphocytes.

REASONS:

- Genetic mutations
- Epigenetic changes

MECHANISM:

HOMEOSTATIC IMBALANCE



500 OVER-EXPRESSION OF ANTI-APOPTIC
 501 GENES
 502 +
 503 PROTO-ONCOGENE MYC
 504 ↓
 505
 506 AGGRESSIVE BETA CELL MALIGNANCIES
 507
 508 (INHIBIT
 509 TOR) ↓
 510
 511 THE DECREASE OF THE PROSPENSITY OF THESE CELLS
 512 FOR APOPTOSIS

INHIBITORS:

- BCL-2 inhibitor
- Bruton's tyrosine kinase inhibitor
- Phosphoinositide-3-kinase inhibitor




Figure05: Chronic Myelogenous Leukemia [9]

MECHANISM:

**DEVELOPMENT & UN-REGULATORY GROWTH
 OF MYELOID BONE MARROW CELLS**



524
 525
 526
 527
 528
 529
 530
 531
 532
 533

534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554

INHIBITORS →

LEUKOCYTOSIS

INHIBITORS:

Tyrosine kinase inhibitors [9]

LYMPHOMA:

2 types of Lymphoma. Hodgkin & Non-Hodgkin lymphoma.




Figure06: Hodgkin Lymphoma [10]

555
556
557
558
559
560
561
562
563
564
565
566
567
568


HODGKIN LYMPHOMA:

- Lack of CD surface antigens results in Hodgkin lymphoma [11].

569
570
571
572
573

•MOPP was initially used to treat Hodgkin lymphoma.

NON-HODGKIN LYMPHOMA:



574
575
576
577
578
579
580
581
582
583
584
585
586
587
588

Figure07: Non-Hodgkin Lymphoma [11]

INHIBITORS:

Rituximab works against CD20, but not active against Hodgkin Lymphoma.

MULTIPLE MYELOMA:






Figure08: Multiple Myeloma [12]

589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623

MECHANISM:



INIBITORS:



624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669


LIMITATIONS OF THE THEOREM:

The vulnerabilities of the current proposal are:


- The Organoids are imperfect for reproductions [2].
- It can affects the therapeutic potential.
- Some organoid lines cannot be expanded, in case of long Term prospects [2].
- Cancer organoids tends to grow slowly [2].
- It just a research proposal, which requires to be worked gradually on the progression of advancement.
- In this study there isn't any discussion about the Acute Monocytic leukemia and its possible treatment.

GENERAL ORGANIDS WORKING DIAGRAM (IN VIVO):

MECHANISM 01:
ORGANOIDS



MECHANISM 02:



670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719

GENERAL ORGANOIDS WORKING DIAGRAM (IN VITRO):

MECHANISM 01:

ORGANOIDS → Genetic Mutations

MECHASIM 02:

ORGANOIDS → CELL GROWTH

MECHANIM 03:

Figuring the tumor immunity → Signal transduction
↑
ORGANOIDS

MECHANISM 04:

ORGANOIDS → Improves cell monitoring
↓
Better drug action

CONCLUSION:

The efficiency of organoid molecules and its prowess towards various types of blood cancer, showing a significant active role to establish an ideal in (vivo-vitro) models. However, the upwardly discussed results and their experiments bespeaking the possible crucial interventions against the cell growths. The role of a 3D cell cultured organoid technology is very useful in terms of possible blockage to the affected tumor stem cells and aiding the transduction mechanism of the normal cell molecules.

Here, The Nano-ranged MRI technology not just only been restricted to its application towards cancerous medications and diagnosis, but also has the power to instrument furtherly to cease the whole associated challenges by providing a possible greater diagnosis and innovative regenerative solutions for the future novel anti-blood cancer therapy.

720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765

REFERENCES:

- [1] Esther Landhuis, Tumor organoids may speed Cancer treatment.vol.195, No.1, January 19, 2019, P.9.
- [2] Xu et al. Journal of Hematology & Oncology, (2018) 11:116, Hanxiao Xu, Xiaodong Lyu, Ming Yi, Weiheng Zhao, Yongping song, and Kong ming Wu, Organoid technology and Applications in cancer research.
- [3] Nagle, P.W. Seminars in Cancer Biology (2018), Patient-derived tumor organoids for prediction of cancer treatment response. June. 2018.
- [4] Kristi Baker, Organoids provide an important window on inflammation on cancer, May 21, 2018.
- [5] Manuela Unbischek, Helena Rannikmae, Thomas Foets, Ktahrina Ravin, Marko Hyvonen, Marc de la Roche. Organoid culture media formulated with growth factors of defined cellular activity. 17th April 2019.
- [6] Acute lymphoblastic leukemia. Wikipedia.
- [7] Acute Myeloid leukemia. Wikipedia.
- [8] Chronic Lymphocytic leukemia. Wikipedia.
- [9] Chronic Myelogenous leukemia. Wikipedia.
- [10] Hodgkin Lymphoma. Wikipedia.
- [11] Non-Hodgkin Lymphoma. Wikipedia.
- [12] Multiple Myeloma. Wikipedia.
- [13] MERCK, DMEM/F12 Media
- [14] What is an MRI (Magnetic Resonance Imaging)? , Live Science.
- [15] A three-dimensional tissue culture model to study Primary human bone marrow & its malignancies.
- [16] ScienCell Research Laboratories, inc.
- [17] Evaluating the varied appearances of Normal & Abnormal Marrow, RAD Source.
- [18] 50 ml centrifuge tube, Pluimate-Pluriselect.
- [19] Freepik
- [20] GE Healthcare, Discovery MR750-60cm, Lease MRI Scanner
- [21] Syringe, Shutter stock
- [22] American Society of Hematology
- [23] Robyn stoller, 7 Facts you need to know about blood cancers, National Foundation for Cancer Research, 13th September, 2017.

766
767 [24]Adrian Herper, MD, PhD, Executive vice president and Chief medical officer, Eagle
768 pharmaceuticals, 12/14/2016, 7:30am, 'Nanotechnology & the New Generation of
769 Injectable Medicines'.
770 [25]Bone Marrow, National Cancer Institute.
771 [26]Real Choices in health & wellness, The Bio Regulator Company.
772 [27]Hera, in vivo solutions available or in development.
773 [28]FLT3, NCBI.
774 [29]Small Molecules, A 83-01, Biogens (A peproTech brand)
775 [30]Enusa Ramani, Economic assessment of
776 Diagnostic systems against neglected diseases
777 In African children under five years of age

778 [31]Hematopoietic stem cells, bioexplorer.net

779 [32]Histology department, Faculty of Medicine, Cairo University.

780 [33] Huayu yang, Lejia sun, Meixi liu, Yilei Mao; Patient derived organoids: a
781 promising model for personalized cancer treatment, Oct9, 2018
782
783
784
785
786
787
788

UNDER PEER REVIEW